Molecular Partners MLLCF Stock
Molecular Partners Price Chart
Molecular Partners MLLCF Financial and Trading Overview
| Molecular Partners stock price | 4.01 USD |
| Previous Close | 4.01 USD |
| Open | 2.55 USD |
| Bid | 3 USD x 10000 |
| Ask | 5.45 USD x 10000 |
| Day's Range | 2.55 - 2.55 USD |
| 52 Week Range | 2.25 - 4.85 USD |
| Volume | 100 USD |
| Avg. Volume | 79 USD |
| Market Cap | 153.6M USD |
| Beta (5Y Monthly) | 0.688 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.71 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
MLLCF Valuation Measures
| Enterprise Value | 88.72M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.1632314 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.745 |
Trading Information
Molecular Partners Stock Price History
| Beta (5Y Monthly) | 0.688 |
| 52-Week Change | 14.57% |
| S&P500 52-Week Change | 10.88% |
| 52 Week High | 4.85 USD |
| 52 Week Low | 2.25 USD |
| 50-Day Moving Average | 3.96 USD |
| 200-Day Moving Average | 3.32 USD |
MLLCF Share Statistics
| Avg. Volume (3 month) | 79 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 38.31M |
| Float | 20.71M |
| Short Ratio | N/A |
| % Held by Insiders | 8.46% |
| % Held by Institutions | 43.82% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.27% |
| Return on Equity (ttm) | -61.96% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -35566000 USD |
| EBITDA | -50850000 USD |
| Net Income Avi to Common (ttm) | -51187000 USD |
| Diluted EPS (ttm) | -1.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 67.93M USD |
| Total Cash Per Share (mrq) | 1.77 USD |
| Total Debt (mrq) | 3.04M USD |
| Total Debt/Equity (mrq) | 5.2 USD |
| Current Ratio (mrq) | 7.274 |
| Book Value Per Share (mrq) | 1.8537085 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -46113000 USD |
| Levered Free Cash Flow (ttm) | -27040624 USD |
Profile of Molecular Partners
| Country | United States |
| State | N/A |
| City | Schlieren |
| Address | Wagistrasse 14 |
| ZIP | 8952 |
| Phone | 41 44 755 77 00 |
| Website | https://www.molecularpartners.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 134 |
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Q&A For Molecular Partners Stock
What is a current MLLCF stock price?
Molecular Partners MLLCF stock price today per share is 4.01 USD.
How to purchase Molecular Partners stock?
You can buy MLLCF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Molecular Partners?
The stock symbol or ticker of Molecular Partners is MLLCF.
Which industry does the Molecular Partners company belong to?
The Molecular Partners industry is Biotechnology.
How many shares does Molecular Partners have in circulation?
The max supply of Molecular Partners shares is 38.31M.
What is Molecular Partners Price to Earnings Ratio (PE Ratio)?
Molecular Partners PE Ratio is now.
What was Molecular Partners earnings per share over the trailing 12 months (TTM)?
Molecular Partners EPS is -1.71 USD over the trailing 12 months.
Which sector does the Molecular Partners company belong to?
The Molecular Partners sector is Healthcare.
